sosou
24小时客服热线 029-88323296

当前位置:

首页 >微创学院 >聚桂醇文献

文献推荐 | 儿童腹膜后淋巴管畸形:腹腔镜引导聚多卡醇泡沫硬化单中心回顾聚桂醇文献

发布时间:2026-10-22 11:03:54 来源: 浏览次数:76

《BMCPediatrics》(2026)26:391

Laparoscopic polidocanol foam sclerotherapy  for retroperitoneal lymphatic malformations  in children: a single center retrospective study

  ShengLin1,2  ,YangwenLin1,2  ,BingZhang1,2,YifanFang1,2andJianxiBai1,2*

  ABSTRACT:Background:    Retroperitoneal lymphatic malformations (LMs) are rare, and their deep location adjacent to critical  structures renders treatment particularly challenging.This retrospective study aims to investigate the safety and  efficacy of laparoscopic polidocanol foam sclerotherapy (LPFS) in the treatment of retroperitoneal LMs in children.  

  Methods:We conducted a retrospective analysis of 12 pediatric patients with retroperitoneal LMs who underwent  LPFS at our institution between July 2020 and July 2025.The procedure involved laparoscopic-guided cyst puncture,  aspiration, and injection of polidocanol foam prepared using the Tessari technique. Key outcomes included operative  details, number of treatment sessions, complications, and treatment response defined by imaging.

  Results:  All 12 patients were successfully completed laparoscopically without conversion to open surgery.The cohort  comprised 2 macrocystic and 10 mixed LMs, with a median maximum diameter of 8.6 cm (range: 5.3–19.3 cm).  Intracystic hemorrhage was noted intraoperatively in 9 cases and adhesions in 5 cases. Complete radiologic resolution  was ultimately achieved in all patients. 10 patients required only a single treatment session, while the remaining  2 achieved complete resolution after a second LPFS session. All ten patients who presented with preoperative  symptoms reported complete and sustained resolution. No major complications, such as vascular injury, visceral  organ damage, or clinical evidence of adhesion-related obstruction, were observed. During a median follow-up of 36  months (range: 7–60 months), there were no cases of recurrence.

  Conclusion:  LPFS is a safe and effective minimally invasive treatment for pediatric retroperitoneal lymphatic  malformations. It may represent a feasible option, particularly for lesions in anatomically complex locations.  

  KEYWORDS  Laparoscopy, Polidocanol foam, Lymphatic malformations, Sclerotherapy, Children, Retroperitoneal

  IntroductionLymphatic malformations (LMs) are congenital vascular  anomalies arising from aberrant development of the lymphatic system [1,  2]. According to the International Society for the Study of Vascular Anomaly (ISSVA), common  LMs can be classified into three types based on the size of  the cyst: macrocystic LMs, microcystic LMs, and mixed  LMs   [3]. While commonly occurring in the head, neck,  and axillary regions, retroperitoneal LMs are exceedingly  rare,   accounting for less than   1%   of all   cases   [4].   This  unique location poses distinct therapeutic challenges, as  the retroperitoneal space harbors vital vascular and visceral structures that these lesions often intimately surround [4,  5].Surgical   excision   has   historically   been   the   primary  curative treatment for retroperitoneal LMs [4]. However,  complete resection in this anatomically complex region  is technically demanding. The procedures are associated  with significant trauma, risks of injury to major vessels  or organs   [6]. Consequently, there is a compelling need  for effective minimally invasive treatment. Sclerotherapy  has emerged as a first-line therapy for macrocystic and  mixed   LMs   in   more   accessible   locations,   offering   the  benefits of minimal invasiveness and reduced morbidity[1].   However,   its   application   to   deep-seated   retroperitoneal lesions via the   conventional percutaneous route  is often limited. Critical limitations include: the risk of  injuring interposed bowel or vessels along the needle trajectory, the inability to adequately manage multiloculated  cysts under blind puncture, and the challenge of ensuring  complete sclerosant distribution [7].To overcome those limitations, laparoscopic-assisted  sclerotherapy has been proposed as a promising hybrid  approach [8]. It combines the precise, direct visualization  of surgical access with the ablative principle of sclerotherapy. Nevertheless, robust clinical evidence regarding  its safety and efficacy, particularly in the pediatric population, remains scarce. This study therefore aims to retrospectively evaluate the clinical outcomes of Laparoscopic  Polidocanol Foam Sclerotherapy (LPFS) for the treatment  of retroperitoneal lymphatic malformations in children,  seeking to provide evidence for its role as a viable minimally invasive treatment option.

Materials and methods  Study population

This single-center, retrospective analysis included pediatric patients diagnosed with retroperitoneal LMs who  underwent LPFS at our institution between July 2020 and  July 2025. The diagnosis was primarily established by preoperative imaging. At our institution, asymptomatic and  non-progressing   small   LMs   are   managed   expectantly.  Active treatment was indicated in this cohort due to the  presence of symptoms, large size, or progressive enlargement.   Demographic   characteristics,   imaging   features,  operative   time,   treatment   sessions,   complications   and  outcomes were   recorded.   The   study was   conducted   in  accordance with the Declaration of Helsinki (as revised  in 2013) and was approved by the Ethics Committee of  Fujian    Children’s    Hospital    (No.:    2023ETKLR05065).  Written informed consent was obtained from the parents  or legal guardians of all participants.

According to our institutional protocol, LPFS was primarily   indicated   for   centrally   located   retroperitoneal  LMs   (Fig.   1A)   where   percutaneous   access   was   unsafe  and where proximity to critical structures posed a high  risk   for   resection.   Laparoscopic   excision   was   reserved  for well-circumscribed lesions away from vital anatomy,  while    percutaneous    sclerotherapy    was    preferred    for  superficial, laterally located cysts. Open surgery was only  performed if malignancy was suspected or prior interventions   had failed. All   patients   in this   series   met the  criteria for LPFS. No eligible patients were excluded or  chose a different treatment during the study period.


Fig. 1   Key procedural steps of laparoscopic polidocanol foam sclerotherapy (LPFS).  A  Preoperative planning: MRI (T2-weighted) reveals a septated, high-signal retroperitoneal lymphatic malformation.  B  Access and targeting: Laparoscopic-assisted puncture is performed, avoiding critical interposed structures.  C  Visual confirmation: The laparoscopic view provides real-time confirmation of safe needle trajectory and intracystic position.  D   Diagnostic aspiration: Cyst content is sampled; the presence of both serous and hemorrhagic fluid aids in diagnosis and operative planning

Inclusion criteria: Patients aged <18 years with a confirmed retroperitoneal LMs who underwent LPFS.Exclusion   criteria:   Patients   with   lymphatic   malformations in other locations requiring a different surgical  approach; those with known   systemic vascular   malformation syndromes; or those with incomplete clinical or  follow-up data.

Laparoscopic polidocanol foam sclerotherapy

All procedures were performed under general anesthesia. Pneumoperitoneum was established (maintained at 8–12mmHg) via a 5-mm umbilical trocar. Under laparoscopic guidance, one or two additional working trocars (3-mm or   5-mm)   were   inserted   under   laparoscopic   guidance. The retroperitoneal lesion was fully exposed and its anatomical relationships were assessed.

A key step involved cyst puncture under direct vision using   an   22-gauge   Veress   needle.   Correct   intracystic position was rigorously confirmed by aspirating characteristic clear, serous, or chylous lymphatic fluid. If frank blood   was   aspirated,   a   critical   distinction   was   made between intracystic hemorrhage and accidental vascular puncture:

1.   Intracystic hemorrhage was indicated by the  aspiration of dark, non-pulsatile blood that typically  ceased after initial drainage, and the cyst wall was  observed to collapse.

2.  Accidental vascular puncture was suspected if brightred, pulsatile blood was aspirated continuously. In  such cases, the needle was immediately withdrawn,pressure was applied laparoscopically, and a newpuncture site was selected.

Onlyafterconfirming an intracystic position was thesclerotherapy proceeded.

Polidocanol foam was prepared intraoperatively using the Tessari method. A three-way stopcock connected two10-mL syringes, one containing 3% polidocanol solution and the other containing room air. With a fixed gas-toliquid ratio of 3:1, the mixture was vigorously agitated through   the   stopcock   for   20   cycles   to   create   a   stable, homogeneous   foam,   which   was   used   within   2   min   of preparation to ensure optimal stability.

After maximal aspiration of cystic fluid, the foam was  injected slowly under continuous laparoscopic visualization until the cyst wall was fully distended or mild reflux  was observed at the puncture site. For multiloculated or  septated   cysts,   individual   locules   were   punctured   and  treated sequentially to ensure complete sclerosant coverage. The operative field was meticulously inspected for  hemostasis and any signs of extracapsular leakage before  trocar removal.

  Outcome measurements and definitionsClassificationLMs were classified according to the International Society for the Study of Vascular Anomalies (ISSVA) classification system [1,  3].

Efficacy endpoints

Treatment response was assessed by imaging (ultrasound or MRI).

Complete resolution was defined as the reduction of the largest single diameter or dominant cystic component to less than 2 cm, is a well-established criterion for differentiating macrocystic from microcystic lesions, with the former being associated with favorable responses to sclerotherapy [9,  10].

Residual lesion  was defined as a persistent cystic structure with a maximum diameter  ≥2 cm at the first postoperative follow-up.

Recurrence  was defined as the reappearance of a cystic lesion  ≥2 cm after documented complete resolution.

 

Safety endpoints

Complications   were   monitored   throughout   follow-up. Specific definitions included.

  Ectopic embolism

  Clinical symptoms (e.g., acute respiratory distress, neurological deficit) with imaging confirmation.

Adhesive intestinal obstruction

Clinical and radiographic  evidence of bowel obstruction requiring intervention.Other complications included allergic reactions, portsite hernia, infection, and intra-abdominal organ injury.

  Follow-up protocol

  Patients were typically discharged 2–3 days postoperatively once they were tolerating a regular diet and were otherwise    asymptomatic.    Systematic    follow-up    was scheduled   at   1   month   postoperatively   with   abdominal ultrasound. If a residual lesion measuring ≥2 cm in maximum diameter and/or causing symptoms was identified, a repeat LPFS session was offered. If complete resolution was confirmed at 1 month, a follow-up abdominal MRI was performed at 6 months postoperatively to establish a baseline for long-term assessment. Patients were then advised to undergo annual clinical and ultrasonographic evaluations thereafter to monitor for late recurrence.

Results

Patient characteristics and operative findings

A total of 12 children (10 males and 2 females)with retroperitoneal lymphatic malformations (LMs) were included in   this   study.   Their   detailed   clinical   characteristics   are summarized in Table 1. The median age at surgery was 48 months (range: 3–156 months). Ten patients (83.3%) presented with abdominal pain, three of whom also experienced vomiting. The remaining two patients (16.7%)were diagnosed prenatally. All diagnoses were confirmed preoperatively via ultrasonography and magnetic resonance imaging   (MRI). Based on MRI findings and the ISSVA classification, there were 2 macrocystic   and   10 mixedtype lesions, with a median maximum diameter of 8.6 cm(range: 5.5–19.3 cm). Intraoperatively, intracystic hemorrhage was noted in 9 cases (75%), and adhesions between the cyst and surrounding omentum or mesentery were encountered in 5 cases   (41.7%), which required careful laparoscopic adhesiolysis to adequately expose and stabilize the cyst for precise puncture.

Table 1   Clinical Characteristics and Outcomes of 12 Pediatric Patients with Retroperitoneal LMs Treated with LPFS

 

 

Treatment efficacy and safety

  All procedures were successfully completed under laparoscopy   without   conversion   to   open   surgery.   The   key operative   steps   are   illustrated   in   Fig.   1.   The   median operative duration was 71 min (range: 45–120 min). All patients   achieved   complete   radiologic   resolution.   Specifically,   10 patients   (83.3%)   achieved   complete   resolution after a single LPFS session. 2 patients (16.7%) with mixed-type lesions had residual cysts (>2 cm) at the first postoperative   ultrasound   (4   weeks)   and   subsequently underwent   a   second   LPFS   session.   Their   initial   lesion diameters were 8.2 cm and 10.0 cm,with post-procedural residuals   measuring   3.2   cm   and   3.5   cm,   respectively. During   the   second   procedure,   dark,   old   hemorrhagic fluid was aspirated from both cysts. Laparoscopically, the cyst walls   appeared   slightly thickened   and   opaque but with clearly discernible boundaries; no dense adhesions or significant tissue plane alterations that could complicate the procedure were encountered. Following the second session, both patients achieved complete radiologic  resolution, with final residual lesions measuring less than2 cm. No major complications—such as vascular injury,  organ perforation, or clinically significant sclerotherapyrelated adverse events—occurred during the procedures  or the immediate postoperative period.

  Follow-up outcomes

  The   median   postoperative   hospital   stay   was   2.8   days(range: 2-5days). All patients were followed up postoperatively with a median duration of 36 months   (range:7–60 months). Follow-up MRI at 6 months and subsequent   annual   ultrasound   examinations   confirmed   sustained complete resolution in all cases. Furthermore, all ten patients who presented with preoperative symptoms reported complete and sustained resolution of symptoms following treatment, correlating with the radiologic findings.   No   recurrence   of the lymphatic   malformation   or long-term complications were observed during the follow-up period.

  Discussion

  This   retrospective   study   demonstrates   that   LPFS   is   a safe   and   effective   minimally   invasive   approach   for   the treatment   of   retroperitoneal   LMs   in   children.   In   our initial   experience with   12   children,   the   procedure was associated with a high rate of complete resolution with no major complications or recurrence observed over a median follow-up period of 36 months.

Interpretation and comparison

For retroperitoneal LMs located in the deep midline, the therapeutic challenge is particularly pronounced. These lesions   are   often   embedded   among   critical   anatomical structures, including major vessels, the kidneys, and intestinal tracts   [11]. Although   complete   surgical   excision has been regarded as the definitive curative treatment with well-established   long-term   outcomes   [4,   6], open surgical excision in this region necessitates extensive dissection within the abdominal and retroperitoneal cavities.   This   approach   not   only   constitutes   considerable invasiveness but also carries a high risk of damaging surrounding tissues   [12]. Moreover, even with open exposure, achieving complete resection can be difficult without undue risk. Laparoscopic resection, as reported in series   [5], represents a significant minimally invasive advance [13]. However, for lesions intricately adherent to vital retroperitoneal structures, complete dissection can be technically challenging and risks injury [5, 14]. In contrast, LPFS achieved complete radiologic resolution in all cases without the need for open conversion, suggesting it may offer a minimally option for achieving the primary therapeutic goal.Sclerotherapy under imaging guidance is a established  minimally   invasive   option,   particularly   for   unilocular  macrocysts.   However,   for   retroperitoneal   LMs,   especially involving the median of retroperitoneal, the position of is deep, surrounded by many complex anatomical  structures, such as intestinal   [15,   16], pancreas, spleen[13] and many important vessels. Direct access to these  deep-seated lesions through the abdominal wall can be  anatomically difficult, and the puncture path may pose a  significant risk of injury to interposed abdominal organs.  In   addition,   ultrasound-guided   injection   of sclerotherapy [15] cannot determine the source of abdominal LMs  which is crucial for the selection of treatment methods[14,   17].   The   laparoscopic   approach   employed   in   our  study potentially addresses this limitation. Firstly, laparoscopy provides direct visualization of the lesion and its  anatomical relationships, allowing for differential diagnosis of cysts and evaluation of its extent [18]. Secondly, the  needle is operated under direct vision not only beneficial  for sclerotherapy, but also less likely to damage abdominal organs.The commonly used sclerosing agents for LMs include ing OK-432, bleomycin, doxycycline, and foam of polidocanol or sodium tetradecyl sulfate   [1,  19]. A particular limitation of liquid agents is the difficulty in visually distinguishing   between   injected   and   uninjected   compartments during the procedure, especially in multicystic or septated lesions with spatial overlap. This can lead to   incomplete treatment   and   potential   post-procedural residue.   To   address   this   issue,   we   employed   polidocanol in a foam formulation. The foam creates a clear and immediate visual contrast within the cyst cavity, allowing   for   real-time   confirmation   of distribution   (Fig.   2).

 

 

Fig. 2   Figure 2 Intraoperative visualization advantage of foam sclerosant.  A  Baseline anatomy: Laparoscopic view of the cyst prior to injection, appearing as a single compartment.   B   Real-time delineation:   Upon foam injection, the treated area (red arrow) is immediately and clearly distinguished from the untreated locule (white arrow) by a sharp demarcation line, revealing the true multiloculated anatomy.  C  Endpoint confirmation: Complete filling of the entire cystic structure with foam, ensuring direct visual confirmation of comprehensive sclerosant distribution and treatment endpoint

  This markedly reduces the likelihood of missing a compartment and the need for repeated punctures, thereby  potentially enhancing the completeness of ablation and  the overall therapeutic efficacy.

  Therefore,       the       favorable       preliminary       outcomes observed in our series might be attributed to the synergistic combination of laparoscopic visualization and the properties of polidocanol foam [20]. Under laparoscopic direct   vision,   the   surgeon   can   systematically   identify, individually   puncture,   and   ensure   complete   foam   filling   of each   sizable locule.   The foam formulation   itself provides an additional advantage, as it fills the cyst, the created visual   contrast   offers   immediate   intraoperative feedback,   confirming   that   the   entire   compartment   is treated and leaving little doubt about untreated areas.

  Clinical implications and technical recommendations

  Notably, intraperitoneal adhesions were encountered in a  substantial subset of our patients (5/12, 41.7%). This finding   likely   reflects   the   chronic,   space-occupying   nature  of large   retroperitoneal   LMs,   which   can   incite   a   local  inflammatory response. The presence of adhesions adds  a layer of complexity to any surgical approach. In open  surgery,   dense   adhesions   increase   the   risk   of visceral  injury during dissection. In percutaneous sclerotherapy,  they   are   undetectable   and   may   fix   bowel   loops   in   the  path of a blind needle, elevating the risk of perforation.  The laparoscopic approach directly addresses this challenge. Crucially, the goal of adhesiolysis in LPFS differs  fundamentally from that in radical excision [21]. Unlike  excision   which   requires   complete   mobilization   of   the  entire lesion, LPFS only necessitates a minimal and targeted adhesiolysis to create a safe puncture window and  working space. This approach allows for precise needle  access while deliberately minimizing unnecessary dissection, thereby reducing the risk of collateral tissue damage and potential bleeding. It is this targeted, rather than  exhaustive, dissection that may have contributed to the  observed variation in operative duration (range: 45–120  min). This principle underscores a key advantage of LPFS  over both open surgery and purely percutaneous techniques: it offers a controlled means to manage anatomical  distortion with inherently less tissue trauma.  In   our   series,   while   all   patients   ultimately   achieved complete resolution, two cases required a second sclerotherapy   session,   highlighting   that    managing    residual lesions is a key focus for refining LPFS. Our experience suggests that several factors may contribute to residual disease:   intracystic   hemorrhage,   which   can   dilute   the sclerosant   and   limit   endothelial   contact   [22];   complex multicystic   anatomy that   hinders   uniform   foam   distribution;   and   potential   foam   extravasation   through   an enlarged   or   multiple   needle   tracts.   To   mitigate   these risks, we recommend integrated procedural refinements:for cysts with hemorrhage, gentle irrigation after aspiration    may    improve    sclerosant    efficacy;    meticulous preoperative MRI review combined with systematic laparoscopic   exploration   is   essential   to   delineate   multicystic structures and reduce missed locales; and operative technique should emphasize minimal needle movement within the cyst, avoiding repeated punctures at the same site to decrease tract size and sclerosant leakage. These technical   adjustments,   derived   from   our   initial   experience, aim to enhance the consistency and completeness of   treatment   in   future   applications.   However,   during the secondary procedures, the residual cysts were easily identifiable   laparoscopically   with   minimal   surrounding adhesions,   facilitating   safe   re-puncture   and   suggesting that the initial foam sclerotherapy does not create a hostile surgical field.Based on the favorable therapeutic outcomes and safety  profile preliminarily observed in this study, laparoscopic  polidocanol foam sclerotherapy   (LPFS) may be considered   a   viable   minimally   invasive   option   for   pediatric  macrocystic or mixed-type retroperitoneal LMs, particularly those located in anatomically complex regions. To  optimize the procedure, our experience highlights several key technical   considerations: if the   cyst   aspiration  yields   frankly bloody fluid,   injection   should be   paused  to   exclude   accidental vascular   puncture;   intraoperative  observations   suggest   that   minimal   foam   leakage   from  the needle tract does not appear to cause clinically significant adhesions, as evidenced in two re-intervention  cases, although meticulous technique to minimize leakage remains essential; and the entire procedure requires  gentle   manipulation,   limiting   needle   movement   within  the cyst and avoiding repeated punctures at the same site,  to prevent tract enlargement, which could lead to sclerosant extravasation and compromised efficacy.

  Limitations

  Several limitations of this study should be acknowledged.  First, the findings are based on a relatively small, singlecenter, retrospective case series, which may limit the statistical power and generalizability of our results. Second,  there is an inherent selection bias as all included patients  were    chosen    for    surgical    intervention.    Furthermore,  although the mean follow-up period of 36 months is adequate for initial assessment, longer-term follow-up would  provide   more   definitive   evidence   regarding   sustained  efficacy and absence of late recurrence. Finally, the lack  of a direct control group precludes comparative effectiveness conclusions.

Conclusion

In    conclusion,   this    study   suggests   that   laparoscopic  polidocanol   foam   sclerotherapy   (LPFS)   is   a   safe   and  effective    minimally    invasive    treatment    for    pediatric  retroperitoneal    LMs   within    our    cohort.    To   validate  and   extend these promising preliminary results, future  research should prioritize conducting larger-scale, multicenter, prospective studies, ideally with randomized controlled designs that directly compare LPFS to standard  treatment   options.   Such   studies   should   aim   to   enroll  more   patients,   incorporate   longer   follow-up   durations,  and further refine the optimal indications for this technique, such as specific cyst sizes, morphological classifications, and anatomical locations.

Abbreviations

LMs               Lymphatic malformations

LPFS             Laparoscopic polidocanol foam sclerotherapy

ISSVA          The International Society for the Study of Vascular Anomaly

Acknowledgements

None.

Authors’contributions

JB, SL and YL conceived and designed the study, acquired the data, drafted  the manuscript, and performed the analysis and interpretation. ZB andYF  critically revised the manuscript. All authors reviewed the final version of the  manuscript.

Funding

Startup Fund for scientific research, Fujian Medical University (Grant number:2022QH1224 and 2024QH1253). Fujian Provincial Natural Science Foundation(Grant number: 2024J011133). Medicine Research Project of Fujian Children’sHospital (Grant number: ETK2025007).

Data availability

The raw data supporting the conclusions of this article will be made available  by the authors, without undue reservation.

  Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Fujian Children’sHospital(2023ETKLR05065) based on the principles of the Declaration of  Helsinki and written informed consent has been obtained from the children  and their parents.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Copyright 2019-2020 中国硬化网 all rights reserved 陕ICP备08100338号-2
Top